## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.3% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($113.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. California Public Employees Retirement System Sells 512,416 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251207T190836 | Neutral | Relevance: 99%
-  The California Public Employees Retirement System recently reduced its stake in Gilead Sciences by 10.9%, selling 512,416 shares, though still retaining over 4.1 million shares valued at approximately $462.9 million. This sale occurred while Gilead reported strong Q3 earnings, exceeding analyst expectations for both EPS and revenue, and announced a quarterly dividend of $0.79 per share. Other institutional investors showed mixed activity, with some increasing their positions in Gilead, while company insiders also sold shares.

**2. Gilead Sciences, Inc. $GILD Shares Sold by Baird Financial Group Inc.**
- Source: MarketBeat | 20251207T082435 | Somewhat-Bullish | Relevance: 98%
- Baird Financial Group Inc. reduced its stake in Gilead Sciences (NASDAQ:GILD) by 4.7% during the second quarter, selling 8,323 shares and maintaining 170,425 shares valued at approximately $18.9 million. This adjustment comes as Gilead reported strong Q3 earnings, exceeding analyst expectations with $2.47 EPS and $7.77 billion in revenue, and forecasting an FY 2025 EPS between $8.05 and $8.25. Despite insider selling by CEO Daniel O'Day and other executives, institutional investors collectively own 83.67% of the company's stock, and Gilead declared a quarterly dividend of $0.79 per share.

**3. Jump Financial LLC Takes Position in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251209T122929 | Bullish | Relevance: 98%
- Jump Financial LLC has acquired a new position of 63,029 shares in Gilead Sciences, Inc. valued at approximately $6.99 million during the second quarter. Several other hedge funds have also adjusted their holdings in the biopharmaceutical company, indicating continued institutional interest. Analysts maintain a "Moderate Buy" consensus rating with a price target of $130.65 for Gilead Sciences.

**4. Gilead Sciences, Inc. $GILD Shares Sold by Bank of Nova Scotia**
- Source: MarketBeat | 20251209T090829 | Somewhat-Bullish | Relevance: 98%
-  Bank of Nova Scotia significantly reduced its stake in Gilead Sciences (NASDAQ:GILD) by 43.4% in Q2, selling 445,433 shares. This reduction leaves them with 580,217 shares valued at approximately $64.3 million, while institutional investors now collectively own about 83.7% of the stock. Despite insider selling activity, Gilead reported strong Q3 earnings, beating EPS and revenue estimates, and analysts maintain a "Moderate Buy" consensus with an average target price of $130.65.

**5. Ossiam Sells 15,066 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251209T130809 | Somewhat-Bullish | Relevance: 98%
-  Ossiam reduced its stake in Gilead Sciences, Inc. by 35.3% in the second quarter, selling 15,066 shares and retaining 27,563 shares valued at $3,056,000. Several other institutional investors also adjusted their positions in the biopharmaceutical company, with Vanguard Group Inc. significantly increasing its holdings. Analysts have a generally positive outlook on Gilead Sciences, with a "Moderate Buy" average rating and a consensus target price of $130.65.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Needham | $140 | $133 | +5% |
| 2025-11-13 | Scotiabank | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Needham | main | Buy |
| 2025-11-13 | Scotiabank | init | Sector Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($10.00M) |
| Sells | 14 ($7.11M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Insider selling cluster: $7.1M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.21 indicates undervaluation relative to growth. Forward P/E 13.7x stretched relative to 7% growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $148.1B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.21 |
| Forward P/E | 13.7 |
| Current P/E | 14.6 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -2.9% to -4.3% (-1.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.3pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.06x) but short-term weakness (below SMA20). MACD histogram bearish (-0.95), momentum weakening. RSI neutral at 40.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.35% (CS: 11) | Weak |
| RSI_14 | 40.4 | Neutral |
| MACD Histogram | -0.95 | Bearish |
| vs SMA20 | 0.959x | Below |
| vs SMA50 | 0.987x | Below |
| vs SMA200 | 1.056x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $119.36
- **Stop Loss:** $113.66 (4.8% risk)
- **Target:** $125.06 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 52
- **Position Value:** $6,206.72
- **Portfolio %:** 6.21%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*